Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?


Retrophin Raises Offer to Acquire Transcept Pharmaceuticals to $4 Per Share

By  +Follow September 19, 2013 8:51AM
Tickers Mentioned:

Retrophin, Inc. (RTRX) is not giving up on its pursuit to acquire the shares of specialty drug maker Transcept Pharmaceuticals, Inc. (TSPT) that it does not already own.  Last week, Retrophin delivered a letter to the board of directors of Transcept offering to buy the remaining shares for $3.50 each in cash.  The offer was rejected. 

To defend itself from a hostile takeover, Transcept has adopted a shareholder rights plan, often called a “poison pill,” which keeps a shareholder from acquiring more than 4.99 percent of the company.

On Wednesday, Retrophin bumped the offer up to $4.00 per share, with Retrophin chief executive Martin Shkreli sending a letter to the board members of Transcept.

Transcept is focused on development of neuroscience drugs with its only FDA approval being the oral sleep aid Intermezzo (zolpidem tartrate).  Purdue Pharma holds commercialization and development right for Intermezzo in the U.S.  Royalty revenue for Transcept from Intermezzo in the first six months of 2013 was $1.0 million, up from $500,000 in the year prior period. 

Net loss for the six months ended June 30, 2013 was approximately $17.2 million, or $0.92 per share, versus a net loss of approximately $10.3 million, or $0.67 per share, for the six months of 2012.

Retrophin has four drugs in its pipeline with RE-021 the only one in the clinical stage, being researched in a mid-stage trial for Focal Segmental Glomerulosclerosis, a disease that can cause nephrotic syndrome in children and kidney failure in adults.  The company’s other compounds are targeting hard-to-treat diseases like Pantothenate Kinase-Associated Neurodegeneration (PKAN) and Duchenne Muscular Dystrophy.

In recent weeks, three major shareholders of Transcept have publicly stated their disapproval of Transcept’s current strategy.  Activist investor Peter Collery of SC Fundamental LLC, which owns a 6.7-percent stake in Transcept, sent a letter to Transcept chief executive, president and director Glenn Oclassen (read the SEC filing) saying that the company needs to use $60 million of its cash to conduct a share repurchase to build value, not pursue “simply wrongheaded,” (but unnamed) projects.

Collery didn’t hold back much in expressing his feelings toward Transept management.  Such as:

“I should note how troubled we are by your presumption that the company’s money is yours to do with as you see fit. You and your fellow directors have a fiduciary duty to company shareholders.”


“I’d like, in closing, also to express my displeasure with the company’s recent grant of nearly 600,000 management stock options with a strike price of $2.93 per share. As described above, the company’s shares may have a current realizable value of $5 or so. Were Transcept to implement a buyback program, that value might rise to $6. Essentially no management skill would be required to realize these values. That the shares trade for less than $3 is a function of shareholders’ distrust of management. It is incredible that management should be granted undervalued stock options as a “reward” for having created that distrust and I would expect that an inquiry into the deliberations surrounding this recent option grant, and particularly, the suitability of the strike price would be quite interesting.”

Roumell Asset Management, LLC, the largest Transcept shareholder at 12.3 percent of the company, has also filed a 13D with the SEC criticizing the management and demanding a share buy-back plan, not an unidentified acquisition.

The new proposal by Retrophin offers to buy Transcept at a 20-percent premium to Tuesday’s closing price.  The price is still lower than the $6 mark that Collery believes can be attained by performing a share repurchase, but this is a little to-may-toes/to-ma-toes because a merged company could benefit similarly, so investors will have to see where the support falls with the new proposal.

“Our proposal represents an attractive premium to Transcept’s trading performance, and we believe that the proposal offers a compelling opportunity for Transcept’s stockholders, particularly in light of Transcept’s risky and controversial acquisition strategy,” stated Martin Shkreli, Chief Executive Officer of Retrophin. “We hope that Transcept’s Board of Directors will respect its stockholders’ wishes and quickly commence discussions with us regarding the proposed transaction.”

Retrophin wants a transaction to be entered into by the end of September.

Shares of TSPT are down about 18 percent in 2013 thanks to a run-up from lows of $2.52 late in August with the acquisition chatter.  At lows, the stock was off about 40 percent.  Shares rose by 8 percent in Wednesday trading to close at $3.59.  In extended trading, shares rose to $3.98.  Retrophin shares edged up about 1 percent on the day to $6.88.  Shares have more than doubled in 2013.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions.

Signup for our daily newsletter and get our best articles emailed right to you!

Results for rtrx
Penny Stock Secret
6 Mar 15 05:53:43
My Friend Made $4 Million Trading Like this! http://t.co/NovWYe2RAx .. $RTRX $CPST $TGTX
6 Mar 15 05:47:55
Retrophin $RTRX Issues Quarterly Earnings Results http://t.co/QRI6AVbGrp
Chasing Stars
5 Mar 15 20:37:39
Stocks Trending Now: http://t.co/TOZZHCEjIZ $AMSF $OREX $PEIX $OREX $RDS.A $DFS $CWT $RTRX $DFS $PBYI $LMCA $PTEN ~
5 Mar 15 20:36:14
We Have A Lot Of New Penny Stock Picks Coming! Get Early Access: http://t.co/akWB5SdOcg $RTRX $CPST $TGTX
Rosner Stocks
5 Mar 15 20:34:08
Stocks Trending Now: http://t.co/0kBSoPqJ6L $YY $TGT $PBYI $PEIX $STLD $RTRX $TGT $NILE $PDCE $DFS $PEIX $VSLR ~
Rosner Stocks
5 Mar 15 20:09:32
Stocks Trending Now: http://t.co/0kBSoPqJ6L $PTEN $AHC $STLD $RDS.A $SRE $VMEM $RDS.A $PDCE $LMCA $RTRX $OREX $NILE ~
Langan Stocks
5 Mar 15 20:07:11
Must join site if you follow $CNAT Click Here: http://t.co/andfmZqW4N Also See: $VSLR $CNAT $RTRX $FWP ~
Rosner Stocks
5 Mar 15 19:56:24
Stocks Trending Now: http://t.co/0kBSoPqJ6L $TGT $FBT $TGT $RTRX $LMCA $CWT $DFS $NILE $FWP $BAC $PDCE $RTRX ~
Chasing Stars
5 Mar 15 19:54:25
Investor opinions on $PDCE Click Here: http://t.co/7mXFYFOjrD Also See: $VMEM $CMA $RTRX $PACW ~
Chasing Stars
5 Mar 15 19:24:51
5 Mar 15 19:16:38
$RTRX - Retrophin (RTRX) CEO Steve Aselage on Q4 2014 Results - Earnings Call Transcript http://t.co/DskmBAiBeC
Rosner Stocks
5 Mar 15 19:14:35
Stocks Trending Now: http://t.co/0kBSoP98fd $CMA $CNAT $OREX $VMEM $PACW $AHC $PDCE $CWT $LMCA $VSLR $CNAT $RTRX ~
Rosner Stocks
5 Mar 15 19:01:19
Stocks Trending Now: http://t.co/0kBSoPqJ6L $CNAT $RTRX $VMEM $CWT $AHC $FWP $DFS $AMSF $RDS.A $ADES $LMCA $RDS.A ~
5 Mar 15 18:59:43
Do you follow $SRE Click Here: http://t.co/2ROde2Wrl2 Also See: $VSLR $RTRX $RDS.A $PEIX ~
Rosner Stocks
5 Mar 15 18:48:29
Stocks Trending Now: http://t.co/0kBSoPqJ6L $RTRX $OREX $RDS.A $YY $RTRX $PDCE $SRE $TGT $CALA $VMEM $FAZ $TGT ~
Chasing Stars
5 Mar 15 18:33:57
Stocks Trending Now: http://t.co/TOZZHCEjIZ $PBYI $AMSF $HP $RDS.A $PEIX $AHC $VMEM $RTRX $HP $AGG $RDS.A $AMSF ~
Chasing Stars
5 Mar 15 18:33:09
interested in $OREX Click Here: http://t.co/p4sveXbP83 Also See: $AMSF $ADES $HP $RTRX ~
Rosner Stocks
5 Mar 15 18:23:36
Stocks Trending Now: http://t.co/0kBSoP98fd $RTRX $PDCE $CMA $FAZ $YY $PEIX $VSLR $FWP $FBT $NILE $CWT $CMA ~
Zachary Prensky
5 Mar 15 16:54:33
@zipjet not odd, it's the oppty. When there are real firms covering stk & asking q's price will be > $20 IMO $RTRX
5 Mar 15 16:50:15
$RTRX Earnings result is already out. Check out historical price reaction after ER. http://t.co/b2yyFlqYrr
5 Mar 15 16:16:54
@Zackfoot $RTRX CGS% ~2%, GM% 98%. A matter of getting costs under control and sales up. It is odd that no one follows enough to ask a ?
Zachary Prensky
5 Mar 15 15:10:53
@vram2000 @zipjet just look at G&A. Point isn't acq cost its gmgns which are fantastic. Basically Thiola&Cheno fund the pipeline $RTRX
5 Mar 15 14:52:02
$RTRX: Retrophin reports 4Q loss: http://t.co/5oLginHaTN
5 Mar 15 14:46:24
#Retrophin : reports 4Q loss http://t.co/13M8QnXmRA $RTRX
5 Mar 15 14:21:02
$RTRX: Retrophin (RTRX) Releases Earnings Results: http://t.co/ytU11PWe9L
Sleek Money
5 Mar 15 14:20:26
Retrophin $RTRX Releases Earnings Results http://t.co/XSDNaXuD6A
5 Mar 15 14:11:12
@Zackfoot $RTRX Liked the claim that there are 4-5,000 potential Thiola patients up from 2,000 and that they are adding more each wk
US Banking News
5 Mar 15 14:11:09
Retrophin $RTRX Posts Quarterly Earnings Results http://t.co/TOhupYng4E
5 Mar 15 14:11:04
$RTRX: Retrophin (RTRX) Posts Quarterly Earnings Results: http://t.co/l9titxfeVF
Michael Grattan
5 Mar 15 14:08:44
@vigkap: So $rtrx does 80 million in revs this year minimum? http://t.co/Dx4s6LpGy8
5 Mar 15 14:06:11
So $rtrx does 80 million in revs this year minimum?
Zachary Prensky
5 Mar 15 14:02:57
Cholic acid FDA approval potentially tilting rev #s much higher in '15. Well done. $RTRX 2/2
Zachary Prensky
5 Mar 15 14:02:19
Kudos to $RTRX CEO Aselage for being transparent on patient #s, forthright about why no '15 rev ests, and adding comment about 1/2
Michael Grattan
5 Mar 15 13:57:52
@Zackfoot: $RTRX : +Sparsanten +RE-024 +RE-034 +650px Thiola +>45 px paying-Cheno + 'new'Cholic +$27m -$84m debt = why this is still #1 ...
Zachary Prensky
5 Mar 15 13:56:10
$RTRX : +Sparsanten +RE-024 +RE-034 +650px Thiola +>45 px paying-Cheno + 'new'Cholic +$27m -$84m debt = why this is still #1 position for us
US Banking News
5 Mar 15 13:42:26
Retrophin announces earnings. ($0.36) EPS. $14.10m revenue. http://t.co/B4LXMJnTfA $RTRX #RTRX
Zachary Prensky
5 Mar 15 13:35:13
$RTRX release does not have any full year rev guidance. My guess is it will be given on conference call, starting now
5 Mar 15 13:31:28
RT @MartinShkreli: $RTRX spent $3.6m looking into consulting agreements and couldnt even get the right answer. refund from cooley please.
5 Mar 15 13:25:08
RT @MartinShkreli: $RTRX spent $3.6m looking into consulting agreements and couldnt even get the right answer. refund from cooley please.
Zachary Prensky
5 Mar 15 13:24:50
2 new PKAN px ex-US for $RTRX RE-024 with US IND in 1H15. 15m Revs solid, gmgn solid, RE-034 surprising; glad to see still in pipeline
Martin Shkreli
5 Mar 15 13:20:49
$RTRX spent $3.6m looking into consulting agreements and couldnt even get the right answer. refund from cooley please.
Tyler Silver
5 Mar 15 13:20:43
Anyone know what $RTRX revs expectations were for this Q?
Breaking News
5 Mar 15 13:16:06
$RTRX: Retrophin Reports Fourth Quarter and Full Year 2014 Financial ...: http://t.co/rpQGDYc3y2
Edmund Sullivan
5 Mar 15 13:12:04
RT @Thug_BioAnalyst: $RTRX >650 patients on Thiola
5 Mar 15 13:11:39
RT @Thug_BioAnalyst: $RTRX >650 patients on Thiola
Thug Biotech Analyst
5 Mar 15 13:11:12
$RTRX >650 patients on Thiola
Healthcare Stocks
5 Mar 15 13:10:40
Retrophin reports Q4 results http://t.co/JyBtoatZlr $RTRX
SA Breaking News
5 Mar 15 13:10:39
Retrophin reports Q4 results http://t.co/WlkrKW9RWX $RTRX
Brad Loncar
5 Mar 15 13:07:42
$RTRX says there are two new PKAN patients on treatment now, so a total of four. Will file a US IND in 1H15.
5 Mar 15 13:07:35
$RTRX - Retrophin Reports Fourth Quarter and Full Year 2014 Financial Results http://t.co/K12Rv4Zq6k
By  +Follow September 19, 2013 8:51AM



blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.